Signal Transduction and Targeted Therapy (Dec 2021)

First-line anti-VEGF plus EGFR-TKI in EGFR-mutant NSCLC: adding the ARTEMIS trial to the puzzle of current evidence

Susanne Hafner

Affiliations

Susanne Hafner: Institute of Pharmacology of Natural Products and Clinical Pharmacology, Ulm University

DOI: https://doi.org/10.1038/s41392-021-00813-y
Journal volume & issue: Vol. 6, no. 1
pp. 1 – 3

Abstract

No abstracts available.

Published in Signal Transduction and Targeted Therapy

ISSN: 2059-3635 (Online)
Publisher: Nature Publishing Group
Country of publisher: United Kingdom
LCC subjects: Medicine; Science: Biology (General)
Website: http://www.nature.com/sigtrans/

About the journal